Diabetes Mellitus, Periodontal Diseases
Conditions
Brief summary
Patient grouping * Group 1 (Type 2 Diabetes Mellitus patients with CPD + SRP and Omega-3) * Group 2 (Type 2 Diabetes Mellitus patients with CPD + SRP) different clinical parameters were recorded ; plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment loss (CAL). 6.Omega-3 poly-unsaturated fatty acids (1000mg) was given as an adjunctive treatment daily for 6 months to group 2, starting 2 weeks after phase 1 therapy.
Detailed description
A parallel design randomized clinical trial was performed involving thirty participants divided into two groups, 15 participants in each group selected from the outpatient clinic in Oral medicine and Periodontology department. Diabetic control was assessed by glycosylated hemoglobin A1c (HbA1c) of blood samples, patients had relatively stable glycemic control, as demonstrated by a difference not exceeding 1% in at least two HbA1c assays over the previous 6 m. HbA1c was assessed at baseline, 3m, and 6m. Patient grouping * Group 1 (Type 2 Diabetes Mellitus patients with CPD + SRP and Omega-3) * Group 2 (Type 2 Diabetes Mellitus patients with CPD + SRP) Periodontal treatment protocol Group 1 and 2 patients were treated by non-surgical approach in following steps: 1. Each patient had received an initial phase of detailed instruction in self-performed plaque control measures using soft toothbrush and interdental cleansing devices. 2. Full mouth SRP using ultrasonic scaler and hand instruments under local anesthesia was performed to each patient in two sessions. 3. Chlorehexidine CHX mouthwash was prescribed for patients to be used twice daily. 4. For each patient, follow up visits every 2 weeks were done to ensure plaque control. 5. Patients were re- examined after 2 weeks (baseline), 3 and 6 months
Interventions
DRUGOmega 3
SRP + OMEGA 3
PROCEDURESRP alone
Scaling and root planning
Sponsors
British University In Egypt
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Patients had type 2 DM for more than 2 years (diagnosed according to the American Diabetes Association criteria), with no other systemic problem. •Subjects had 14 or more natural teeth, of which at least five had a site with probing pocket depth (PPD) ≥ 5 mm and clinical attachment level ≥ 3 mm. From this point, according to the American Academy of Periodontology, subjects with moderate to severe periodontitis were included
Exclusion criteria
* Pregnant and breastfeeding women, smokers or former smokers, patients with other autoimmune or systemic disease, those patients who took antibiotics in the last 6 months and patients weren't willing to follow our study protocol or plaque regimen
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum level of chemerin | 6 months | Serum level of chemerin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| periodontal clinical parameters | 6 months | PD in mm |
| hba1c | 6 months | Glycated Heamoglobin |
| GCF level of chemerin | 6 months | GCF level of chemerin |
Countries
Egypt
Outcome results
None listed